Molbio &UE LifeSciences Partner to Expand Painless Breast Cancer Screening

• Molbio partners with UE LifeSciences to bring iBreastExam to 50+ developing nations.
• Focus on early breast cancer detection across India, Africa, Southeast Asia, and more.
• iBreastExam offers fast, painless, radiation free screening via a portable, FDA cleared device.

Molbio Diagnostics, known for its innovation in point of care diagnostics, has teamed up with Philadelphia based UE LifeSciences to globally scale access to iBreastExam, a breakthrough breast cancer screening device. The collaboration aims to transform women’s health in over 50 developing countries by offering accessible, painless, and radiation free breast cancer screening.

The partnership will bring iBreastExam to regions including India, Africa, Middle East, Southeast Asia, and CIS countries, where access to early screening is limited. Molbio will use its established healthcare distribution network to promote and supply the device to both government and private healthcare systems.

The iBreastExam is a small, battery powered, portable device that uses advanced sensor technology to detect breast lumps in just minutes. It requires no radiation, causes no pain, and doesn’t rely on large scale medical infrastructure, making it ideal for rural and underserved communities. The results are securely stored on the cloud for easy access and follow up.

Also Read: Mahajan and Fortis La Femme Partner for Better Child Healthcare & Diagnosis in India

Mihir Shah, Founder and CEO of UE LifeSciences, said the partnership with Molbio is a major step toward closing the gap in early breast health screening. “Molbio’s reach and experience make them an ideal partner to deliver impactful health solutions where they’re needed most”, he added.

With breast cancer being the most common cancer among women, especially in developing countries, the duo hopes to save countless lives through early detection and timely intervention.